A phase 1 study of chemosensitization with plerixafor plus G-CSF in adults with relapsed acute myeloid leukemia.

[1]  G. Schuurhuis,et al.  Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia , 2018, Journal of visualized experiments : JoVE.

[2]  J. Esteve,et al.  A phase I–II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia , 2018, Annals of Hematology.

[3]  G. Salles,et al.  High frequency of CD34+CD38-/low immature leukemia cells is correlated with unfavorable prognosis in acute myeloid leukemia , 2017, World journal of stem cells.

[4]  M. Absalon,et al.  A phase 1 study of the CXCR4 antagonist plerixafor in combination with high‐dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators’ Consortium study (POE 10‐03) , 2017, Pediatric blood & cancer.

[5]  H. Dombret,et al.  Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  A. Plesa,et al.  Higher percentage of CD34 + CD38− cells detected by multiparameter flow cytometry from leukapheresis products predicts unsustained complete remission in acute myeloid leukemia , 2015, Leukemia & lymphoma.

[7]  A. Plesa,et al.  Mobilization of CD34(+)CD38(-) hematopoietic stem cells after priming in acute myeloid leukemia. , 2013, World journal of stem cells.

[8]  J. Cayuela,et al.  Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. , 2013, Blood.

[9]  M. Konopleva,et al.  Mobilization and Elimination of FLT3-ITD+ Acute Myelogenous Leukemia (AML) Stem/Progenitor Cells by Plerixafor/G-CSF/Sorafenib: Results From a Phase I Trial in Relapsed/Refractory AML Patients , 2012 .

[10]  R. Vij,et al.  A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. , 2012, Blood.

[11]  H. Dombret,et al.  Which AML subsets benefit from leukemic cell priming during chemotherapy? Long‐term analysis of the ALFA‐9802 GM‐CSF study , 2010, Cancer.

[12]  Julie L Prior,et al.  Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. , 2009, Blood.

[13]  E. Estey,et al.  Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. , 2009, Blood.

[14]  X. Thomas.  The role of timed sequential chemotherapy in adult acute myelogenous leukemia , 2008, Current hematologic malignancy reports.

[15]  Yoon-Chi Han,et al.  CXCR4 is required for the quiescence of primitive hematopoietic cells , 2008, The Journal of experimental medicine.

[16]  G. Schuurhuis,et al.  Aberrant marker expression patterns on the CD34+CD38− stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission , 2007, Leukemia.

[17]  E. Estey,et al.  Overexpression of CXCR4 predicts adverse overall and event‐free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype , 2007, Cancer.

[18]  T. Lister,et al.  Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. , 2005, Blood.

[19]  Augustin Ferrant,et al.  Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. , 2003, The New England journal of medicine.

[20]  D. Howard,et al.  Preferential induction of apoptosis for primary human leukemic stem cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.